Neuraxis, INC

Name: Neuraxis, INC standardized financial statements, quarterly
Creator: Listed

NRXSNYSECIK 1933567HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.9m, Q2 FY2026

Operating income−$2.1m, Q2 FY2026

Net income−$2.1m, Q2 FY2026

Neuraxis, INC, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	477	531	647	612	667	761	896	894	811	968	1,608	1,929
Cost of revenue	$k	67.3	72.3	75.1	73.5	97.1	105	139	147	135	142	218	273
Gross profit	$k	410	459	572	538	570	656	756	747	676	826	1,390	1,656
Research and development	$k	45.0	(2.2)	5.6	54.3	126	138	118	115	131	146	99.6	274
Operating income	$k	(3,022)	(1,623)	(1,832)	(2,207)	(1,651)	(1,467)	(2,295)	(1,718)	(2,100)	(1,717)	(1,741)	(2,125)
Interest expense	$k	103	22.5	26.6	80.7	64.7	2.4	2.2	13.4	29.7	28.6	26.2	19.8
Net income	$k	(8,625)	(1,592)	(2,121)	(2,918)	(1,755)	(1,448)	(2,279)	(1,690)	(2,123)	(1,709)	(1,761)	(2,086)
Diluted EPS	$ per share	(2.38)	not reported	(0.32)	(0.42)	(0.25)	not reported	(0.33)	(0.22)	(0.24)	not reported	(0.18)	(0.19)
Basic EPS	$ per share	(2.38)	not reported	(0.32)	(0.42)	(0.25)	not reported	(0.33)	(0.22)	(0.24)	not reported	(0.18)	(0.19)

Balance sheet

Cash and equivalents$8.3m, Q2 FY2026

Shareholders' equity$6.7m, Q2 FY2026

Neuraxis, INC, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$k	761	78.6	81.8	1,765	261	3,697	2,005	5,988	4,377	4,965	7,079	8,322
Current assets	$k	967	243	408	2,112	632	4,266	2,541	6,619	4,988	5,733	8,143	9,414
Total assets	$k	1,236	509	946	2,633	1,143	4,758	3,030	7,088	5,776	6,404	8,746	9,996
Current liabilities	$k	2,258	1,886	3,816	7,594	2,664	2,433	2,101	2,347	3,147	2,792	2,814	3,096
Total liabilities	$k	2,297	1,913	4,130	7,892	2,937	2,690	2,771	2,835	3,491	3,005	2,998	3,261
Long-term debt	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$k	194	148	1,396	4,767	148	154	84.3	121	196	148	101	42.7
Shareholders' equity	$k	(1,061)	(1,403)	(3,184)	(5,258)	(1,794)	2,068	258	4,253	2,285	3,399	5,748	6,735

Cash flow

Operating cash flow−$1.0m, Q2 FY2026

Capital expenditure$5.9k, Q4 FY2025

Neuraxis, INC, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(2,816)	(2,630)	(1,332)	(1,615)	(1,393)	(1,758)	(1,604)	(1,467)	(1,428)	(1,934)	(1,230)	(1,030)
Capital expenditure	$k	2.7	16.0	14.7	8.7	4.4	0.0	18.0	7.3	0.0	5.9	not reported	not reported
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)12.12m, Q2 FY2026

Neuraxis, INC, shares, quarterly
Line item	Unit	period not labelled2022-09-30	period not labelled2023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	2.0	2.0	2.0	3.6	6.6	6.9	7.2	7.5	8.5	9.9	10.9	12.1

Shares outstanding: 12.56m at Aug 6, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.